H.R. 9061

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 9061 Introduced in House (IH)]

<DOC>

119th CONGRESS
2d Session
H. R. 9061

To amend title XIX of the Social Security Act to require the Secretary 
of Health and Human Services to issue guidance to States on which tests 
for the screening and early detection of preeclampsia may be covered 
under the Medicaid program and the Children's Health Insurance Program.

_______________________________________________________________________

IN THE HOUSE OF REPRESENTATIVES

May 29, 2026

Mr. Kean (for himself, Ms. Kelly of Illinois, Mrs. Kiggans of Virginia, 
and Ms. Clarke of New York) introduced the following bill; which was 
referred to the Committee on Energy and Commerce

_______________________________________________________________________

A BILL

To amend title XIX of the Social Security Act to require the Secretary 
of Health and Human Services to issue guidance to States on which tests 
for the screening and early detection of preeclampsia may be covered 
under the Medicaid program and the Children's Health Insurance Program.

Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the ``Preeclampsia Risk Evaluation and 
Evidence-based Management through Personalized Testing Act'' or the 
``PREEMPT Act''.

SEC. 2. FINDINGS.

Congress finds the following:
(1) According to the Centers for Disease Control and 
Prevention, preeclampsia affects approximately 5 to 8 percent 
of pregnancies globally, with 70,000 maternal deaths and 
500,000 fetal deaths each year in the United States.
(2) In the United States, Black women are at least three 
times more likely to die due to a pregnancy-related cause when 
compared to White women.
(3) Preeclampsia and related cardiovascular and 
hypertensive disorders of pregnancy are one of the leading 
causes of maternal mortality and morbidity in the United 
States, contributing to up to 15 percent of all maternal 
deaths, particularly in States with the highest-risk 
populations and in low resource settings.
(4) Preeclampsia is a major contributor to preterm births, 
accounting for about 15 to 20 percent of all preterm deliveries 
in the United States.
(5) The annual economic burden of preeclampsia in the 
United States exceeds $2 billion, including both direct health 
care costs to mother and baby, and indirect losses due to long-
term health complications and lost productivity.
(6) Risk factors for preeclampsia include maternal age, 
pre-existing diabetes, pregnancies with multiples, chronic 
hypertension, obesity, multiple pregnancies, and certain 
autoimmune diseases, all of which can increase the likelihood 
of developing this condition.
(7) Women who develop preeclampsia during pregnancy have an 
elevated risk of long-term cardiovascular complications, 
including chronic hypertension, heart disease and stroke.

SEC. 3. GUIDANCE ON MEDICAID COVERAGE OF PREECLAMPSIA SCREENING AND 
DETECTION TESTS.

Title XIX of the Social Security Act (42 U.S.C. 1396 et seq.) is 
amended by inserting after section 1948 the following new section:

``SEC. 1949. GUIDANCE AND TECHNICAL ASSISTANCE WITH RESPECT TO COVERAGE 
OF PREECLAMPSIA SCREENING AND DETECTION TESTS.

``(a) Guidance.--Not later than the date that is 180 days after the 
date of the enactment of this section, the Secretary shall issue 
guidance to States and, as appropriate, medicaid managed care 
organizations, on--
``(1) best practices for improving outcomes for pregnant 
women with preeclampsia who are eligible for and receiving 
medical assistance under a State plan (or waiver of such plan) 
under this title or a State child health plan (or waiver of 
such plan) under title XXI through early screening, detection, 
and management; and
``(2) which tests for the early detection of preeclampsia 
may be furnished to such pregnant women as medical assistance 
under such a State plan (or waiver) or such a State child 
health plan (or waiver), including whether the biomarker tests 
described in subsection (c) may be so furnished.
``(b) Technical Assistance.--
``(1) In general.--The Secretary shall, not later than 30 
days after receipt of a request from a State for technical 
assistance with respect to determining whether a State plan or 
State child health plan may provide medical assistance for a 
specific test for the early detection of preeclampsia, 
including a biomarker test described in subsection (c), provide 
such technical assistance to such State.
``(2) Rule of construction.--Nothing in this subsection 
shall be construed as creating a requirement for a State to 
request or receive the technical assistance described in 
paragraph (1) as a condition of providing medical assistance 
for a specific test for the early detection of preeclampsia, or 
of receiving Federal financial participation for such medical 
assistance.
``(c) Biomarker Tests To Be Considered.--For purposes of this 
section, the Secretary shall consider advanced biomarker tests for the 
early detection of preeclampsia, including any such test that is 
regulated and cleared under the Federal Food, Drug, and Cosmetic Act as 
a device (as defined in section 201(h) of such Act), and any such 
laboratory-developed testing service furnished by a clinical laboratory 
that is certified under section 353 of the Public Health Service Act to 
perform high-complexity testing.''.
<all>